Approval in Europe adds to existing approvals in the U.S., Australia and Singapore, according to a news release. The company says this milestone paves the way for the utilization of Mona Lisa 2.0 across 32 additional countries.

Biobot designed Mona Lisa as a robotic-assisted transperineal needle positioning device for prostate disease management. It delivers a precision percutaneous approach to these procedures. The company hopes to use funds to bring it into the field of benign prostatic hyperplasia (BPH) as well.

Mona LIsa 2.0 supports precise targeting and flexibility in prostate biopsies and ablations. It enables the adjustment of the prostate model and needle locations in real-time to account for shifts during the procedure. The platform supports precision in both diagnostic and therapeutic interventions and ensures accurate treatments even in dynamic scenarios.